Efficient reprogramming of human and mouse primary extra-embryonic cells to pluripotent stem cells

Practical clinical applications for current induced pluripotent stem cell (iPSC) technologies are hindered by very low generation efficiencies. Here, we demonstrate that newborn human (h) and mouse (m) extra-embryonic amnion (AM) and yolk-sac (YS) cells, in which endogenous KLF4/Klf4, c-MYC/c-Myc an...

Full description

Saved in:
Bibliographic Details
Published inGenes to cells : devoted to molecular & cellular mechanisms Vol. 14; no. 12; pp. 1395 - 1404
Main Authors Nagata, Shogo, Toyoda, Masashi, Yamaguchi, Shinpei, Hirano, Kunio, Makino, Hatsune, Nishino, Koichiro, Miyagawa, Yoshitaka, Okita, Hajime, Kiyokawa, Nobutaka, Nakagawa, Masato, Yamanaka, Shinya, Akutsu, Hidenori, Umezawa, Akihiro, Tada, Takashi
Format Journal Article
LanguageEnglish
Published Oxford, UK Oxford, UK : Blackwell Publishing Ltd 01.12.2009
Blackwell Publishing Ltd
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Practical clinical applications for current induced pluripotent stem cell (iPSC) technologies are hindered by very low generation efficiencies. Here, we demonstrate that newborn human (h) and mouse (m) extra-embryonic amnion (AM) and yolk-sac (YS) cells, in which endogenous KLF4/Klf4, c-MYC/c-Myc and RONIN/Ronin are expressed, can be reprogrammed to hiPSCs and miPSCs with efficiencies for AM cells of 0.02% and 0.1%, respectively. Both hiPSC and miPSCs are indistinguishable from embryonic stem cells in colony morphology, expression of pluripotency markers, global gene expression profile, DNA methylation status of OCT4 and NANOG, teratoma formation and, in the case of miPSCs, generation of germline transmissible chimeric mice. As copious amounts of human AM cells can be collected without invasion, and stored long term by conventional means without requirement for in vitro culture, they represent an ideal source for cell banking and subsequent 'on demand' generation of hiPSCs for personal regenerative and pharmaceutical applications.
Bibliography:http://dx.doi.org/10.1111/j.1365-2443.2009.01356.x
Communicated by
Fuyuki Ishikawa
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1356-9597
1365-2443
1365-2443
DOI:10.1111/j.1365-2443.2009.01356.x